Harman Patil (Editor)

Baxalta

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Former type
  
Subsidiary

Fate
  
Acquired by Shire

Founded
  
2015

Industry
  
Biotechnology

Number of employees
  
16,000

Defunct
  
2016


Key people
  
Ludwig N. Hantson (president and CEO)

Products
  
Hematology, Immunology, Pulmonology

Headquarters
  
Bannockburn, Illinois, United States

CEO
  
Ludwig N. Hantson (1 Jul 2015–)

Baxalta (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound') was a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. with revenue of $6 billion.

Contents

2015 baxalta b1 b5 teambuilding hd 1080p


Company history

Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol (a German company) for US$225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for US$900 million.

In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company increasing the Baxalta share price over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3. This deal would create the largest global biotech company focused solely on rare diseases.

In January 2016, after six months of negotiations, the company agreed to be acquired by Shire for $32 billion. The deal was completed on 3 June 2016.

Pipeline

Hematology
  • BAX 855 – long-acting pegylated full-length rFVIII hemophilia A drug awaiting FDA approval in conjunction with Nektar Therapeutics. It is also undergoing Phase II trials for sickle cell.
  • BAX 111 – submitted as a recombinant von Willebrand factor treatment for von Willebrand disease, filed with the FDA in December 2014. In August 2015, data was released and published in the journal Blood, which indicated that 100 percent of the patients treated with BAX 111 were successful in the management of bleeding episodes.
  • BAX 817 – Recombinant factor VIIa
  • BAX 335 – FIX gene therapy in Phase II.
  • BAX 930 – Recombinant ADAMTS13
  • BAX 826 – Recombinant, extended half-life Factor VIII
  • BAX 888 – Factor VIII gene therapy in Phase I trials.
    • Immunology
  • BAX 2200 – Psoriasis drug in Phase III.
  • SM101 - As of 2015, had completed Phase IIA studies in idiopathic thrombocytopenic purpura
  • SM201 / SM211
  • SM301
  • BAX 923 – a biosimilar version of Adalimumab.
  • BAX 1415
    • Oncology
  • MM-398 – Co-developed with Merrimack Pharmaceuticals. Undergoing EU reviews for post-Gemcitabine pancreatic cancer, in Phase III trials for gastric cancer Currently undergoing priority review with the FDA for a new drug application.
  • Pacritinib – Phase III trials for Myelofibrosis, Phase I trials for Acute Myeloid Leukemia and pre-clinical for Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome and Polycythemia Vera.
  • Rigosertib – Phase III trials for Myelodysplastic Syndrome.
  • BAX 069 – also known as Imalumab, in Phase II trials for Malignant Ascites and Metastatic Colorectal cancer.

    • References

    Baxalta Wikipedia
    (Text) CC BY-SA